Aethlon Medical (NASDAQ:AEMD) Stock Crosses Below 200-Day Moving Average – Here’s Why

Aethlon Medical, Inc. (NASDAQ:AEMD)’s share price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $10.46 and traded as low as $3.05. Aethlon Medical shares last traded at $3.05, with a volume of 72,034 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AEMD shares. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a research report on Saturday, August 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $560.00.

Aethlon Medical Trading Down 10.3%

The stock’s 50-day moving average is $4.82 and its 200-day moving average is $10.46. The stock has a market cap of $2.32 million, a price-to-earnings ratio of -0.13 and a beta of 1.64.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by ($2.04). On average, equities analysts predict that Aethlon Medical, Inc. will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Armistice Capital LLC bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,427,946 shares of the medical equipment provider’s stock, valued at approximately $511,000. Armistice Capital LLC owned 8.89% of Aethlon Medical at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.